This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

24 May 2018

Tjoapack wins packaging contract for bladder cancer detection products

Tjoapack to perform the secondary packaging and assembly of product kits for supply to 25 European countries, the US, Canada and Australia.

Global contract packaging organisation, Tjoapack, has signed a 5-year agreement with Photocure for the packaging of its proprietary bladder cancer detection products.

Hexvix/Cysview is a drug that is selectively taken up by cancer cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLCTM). BLCTM with Hexvix/Cysview improves the detection of tumours and leads to more complete resection, less residual tumours and better management decisions.

The contract will see Tjoapack perform the secondary packaging and assembly of product kits for supply to 25 European countries, the US, Canada and Australia.

Dexter Tjoa, Director Corporate Strategy at Tjoapack said: “We’re delighted to be working with a company like Photocure whose technology can make such a difference to patients.

“Photocure has a global customer base, which comes with many potential challenges. At Tjoapack, we have a huge amount of experience in meeting the demands of multiple markets, especially when it comes to complying with legislation, such as artwork requirements and serialisation.

“In addition, the flexibility offered by our on-site warehousing facility will allow us to ensure continued supply in the shortest possible lead times. We hope this will be the start of a long and successful partnership.”

During the project, Tjoapack will be working with semi-finished stock stored at its facility, only finalising and assembling kits when orders come in.

Gry Stensrud, VP of Technical Development & Operations, at Photocure said: “Photocure delivers transformative solutions to improve the lives of bladder cancer patients. This is very much in line with Tjoapack’s ethos which was a big decision-making factor for us when choosing a partner.

“We were also specifically looking for a supplier who was ready for serialisation. While our product does not need to be serialised in the US as imaging drugs are exempt there, compliance with the EU FMD is vital to ensure continuous supply to our European markets.

“We were impressed by Tjoapack’s expertise in this area and are confident they’ll be able to meet our requirements.”

Mentioned Companies
View company profile

Related News